Company Encyclopedia
View More
name
Bayer AG
BAYN.DE
News
View More

Bayer AG Earnings Call: Growth Amid Challenges

Bayer AG's Q3 earnings call highlighted robust growth in its Pharmaceuticals division, driven by strong sales of Nubeqa and Kerendia. Beyonttra achieved significant market share in Germany. The Crop Science division saw a 22% increase in corn sales. However, Bayer faces financial challenges with negative free cash flow and high debt, market difficulties in Consumer Health, and litigation risks. Despite these issues, Bayer remains optimistic about meeting its 2025 guidance, supported by new products like Beyonttra and Lynkuet.

Tip Ranks·
DE
BAYN
0.00%
Tip Ranks·
DE
BAYN
0.00%

Bayer AG Publishes Transcript of Q3 2025 Investor Call

Bayer AG Publishes Transcript of Q3 2025 Investor Call

Reuters·
DE
BAYN
0.00%
Reuters·
DE
BAYN
0.00%

Bayer AG Appoints Judith Hartmann as New CFO

Bayer AG has appointed Dr. Judith Hartmann as the new Chief Financial Officer, effective June 1, 2026. She will join the Board of Management on March 1, 2026, succeeding Wolfgang Nickl, who is retiring. Dr. Hartmann has previously held senior financial positions at ENGIE, Bertelsmann, and General Electric, and is currently an Operating Partner at Sandbrook Capital.

Reuters·
DE
BAYN
0.00%
Reuters·
DE
BAYN
0.00%

Bayer's KERENDIA Achieves Primary Endpoint in Phase III Trial for Type 1 Diabetes and Chronic Kidney Disease

Bayer AG announced that its KERENDIA® (finerenone) achieved a significant reduction in urine albumin-to-creatinine ratio (UACR) by 25% in a Phase III trial for adults with type 1 diabetes and chronic kidney disease. The results were presented at the ASN Kidney Week 2025, and Bayer plans to submit a supplemental New Drug Application to the U.S. FDA in 2026 based on these findings. Additionally, data from the Phase II CONFIDENCE trial will also be presented at the event.

Reuters·
DE
BAYN
0.00%
Reuters·
DE
BAYN
0.00%

HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health

HMI-115, a human monoclonal antibody targeting the prolactin receptor, has shown promising results in a Phase II clinical trial for treating endometriosis-related pain. The trial, published in The Lancet, demonstrated significant reductions in dysmenorrhea and non-menstrual pelvic pain across various dosage groups, with sustained efficacy observed. Unlike existing hormonal therapies, HMI-115 did not cause hypoestrogenic side effects. The findings support further Phase III trials to evaluate its clinical benefits. Hope Medicine has a licensing agreement with Bayer AG for HMI-115's development and commercialization.

MorningStar·
DE
BAYN
0.00%
MorningStar·
DE
BAYN
0.00%